Articles tagged with Blood Cancer
The study found that only 16% of newly diagnosed patients with MDS on Medicare received HMAs during the period analyzed, with women and non-white patients being less likely to start treatment. The analysis suggests that making changes with existing therapies and administration can have a huge impact on improving outcomes in high-risk MDS.
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
A new study has found that TAF1 operates as a key molecular switch in adult hematopoietic stem cell maintenance and lineage commitment. This discovery challenges prevailing models of gene regulation and has the potential to lead to new therapeutic strategies targeting the molecule, which could improve blood production and transplantation.
A new breath test has been developed to detect blood cancers, showing promise for early diagnosis and treatment monitoring. The test uses exhaled breath analysis to identify molecules produced by cancer cells, potentially providing a quick and affordable diagnostic tool for areas with limited access to specialist equipment.
New research from Sylvester Comprehensive Cancer Center shows that partial match transplants can achieve good outcomes with cyclophosphamide treatment. Additionally, lifestyle medicine is playing a pivotal role in improving patient outcomes for cancer survivors.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
Researchers developed a novel immunotherapy that disrupts the IL-33/IL1RL1 signaling loop to boost immune function and improve survival in leukemia patients. The treatment targeted leukemia stem cells, reducing relapse rates and improving survival without major side effects.
The Damon Runyon Cancer Research Foundation has awarded $4.2 million to five new Clinical Investigators conducting patient-oriented cancer research. The awards will support the development of new treatments for cancer patients, with a focus on enhancing efficacy and safety.
The revised guidelines incorporate the latest clinical advances in graft-versus-host disease prophylaxis, expanded donor options and search strategies. The updated guidelines aim to enhance transplant outcomes for patients with blood cancers and disorders.
A new bioinformatic tool called Cell Marker Accordion has been developed to help researchers understand single-cell analysis results. The tool reveals the presence of altered cells that may be linked to diseases such as blood cancers or solid tumours, and can identify unique genes involved in these alterations.
A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.
Researchers created a powerful cell culture model using induced pluripotent stem cells from a patient with MDS, confirming that the CEBPA mutation drives disease progression. The model could lead to new ways to treat and diagnose MDS and avoid more serious conditions.
Scientists have developed a miniature device that mimics human bone marrow and immune environment, enabling predictive testing of cancer immunotherapy success in patients. The device recreates three regions of bone marrow where leukemia develops and retains the complex immune environment of the tissue.
A recent study found that blood cancer patients achieve good outcomes with a partial match drawn from the national public registry of donors when treated with cyclophosphamide. Survival rates at one year were comparable to those seen in other studies with fully matched donors.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
A phase 1 clinical study will assess the safety and efficacy of JBZ-001 in patients with AML. The study is supported by a $3.4 million grant from the National Cancer Institute and aims to improve efficiency for the therapeutic pipeline.
Researchers developed a tool to monitor treatment response in patients with solid tumours using circulating tumour DNA analysis, anticipating clinical relapses up to 68 months before symptoms become apparent. The technology is minimally invasive and can be tailored to each tumour type, reducing unnecessary treatments and costs.
Nancy A. Speck has been recognized for her groundbreaking research on hematopoiesis and leukemogenesis, with a focus on the transcription factor complex core binding factor. Her work has provided critical knowledge to understand how certain blood cancers develop, leading to significant insights in embryonic blood cell formation.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
A Phase I/II study has demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN) treated with pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123. The overall response rate was 85%, including a complete response rate of 70%.
A high-fiber plant-based diet improved health markers that could delay the progression of precancerous conditions and multiple myeloma. The study showed significant improvements in dietary quality, weight loss, metabolic markers, inflammation, and gut microbiome diversity.
In an international clinical trial, a new CAR-T cell immunotherapy demonstrated promising results against aggressive blood cancers, including T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma. Most patients who received the full dose of cells achieved full remission, with response rates ranging from 70-90%.
A new four-drug combination, DKRd, has emerged as a highly effective and safe treatment for newly diagnosed multiple myeloma patients. The ADVANCE clinical trial shows that 59% of patients treated with DKRd were MRD-negative after eight cycles of treatment, compared to 36% of KRd-treated patients.
Researchers have developed a new treatment combining venetoclax and inobrodib that shows promising results in killing B-ALL cells, potentially reducing toxic chemotherapy needs. The approach could be less toxic than current treatments and effective in all age groups.
A study found that blood cancer survivors are more likely to face financial hardship and take fewer medications due to high-cost immunotherapy treatments. Financial strain affects both Medicare-insured and uninsured patients, highlighting the need for better financial support and policy strategies.
Researchers identified two distinct epigenetic profiles in Burkitt Lymphoma, one associated with a favorable clinical course and the other with early relapse and shorter survival. This discovery has implications for treatment strategies and may lead to personalized medicine approaches.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
A USC team has developed an advanced platform to analyze chimeric antigen receptor (CAR) T cells, revealing how their manufacturing conditions impact effectiveness. The tool uses laser technology to analyze 36 characteristics of a single cell, providing a clearer view of CAR T cell behavior.
Researchers at Mass General Brigham found that patients with relapsed/refractory mature T- and NK-cell lymphomas had improved survival rates when treated with small molecule inhibitors as second-line therapy, followed by epigenetic modifiers as third-line therapy. The study, published in the British Journal of Haematolog, also showed t...
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers have discovered that a single mutation in the DNA sequence for methylation enzyme DNMT3A causes faulty gene expression, leading to increased blood cancer risk. This finding confirms DNMT3A as a potential target for effective blood cancer treatment.
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
A phase 1 trial involving 40 patients showed significant responses to the new cell therapy IMA203, with half of non-responders achieving lasting response. The therapy targets PRAME peptide produced by many tumors and was well-tolerated.
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) taking statin medications at the start of treatment had a significantly lower risk of dying from their cancer. Statin use reduced death rates by 61% compared to non-statin users.
Dr Ari Melnick brings extensive experience to the institute, with a focus on precision medicine and haematological diseases. He aims to accelerate innovative treatments and enhance patient outcomes through strong partnerships with leading hospitals and research centres.
A survey by Roswell Park Comprehensive Cancer Center found that 65% of Americans are unfamiliar with CAR T-cell therapy, a personalized cancer treatment option. The therapy involves extracting and engineering immune cells to recognize and kill cancer cells, with promising results in treating blood cancers.
Aging-associated mutations in the Dnmt3a gene boost mitochondria power in blood stem cells, leading to clonal hematopoiesis. New mitochondrial-targeting drugs show promise in treating age-related illnesses by selectively weakening mutated cells without impacting normal ones.
A new combination therapy using cemiplimab and isatuximab has shown promising results in a phase 2 clinical trial for extranodal NK/T-cell lymphoma, with 51% of patients achieving complete response. The study validated genomic biomarkers and a prognostic model developed by the National Cancer Centre Singapore, offering potential for mo...
Researchers have developed an innovative optical genome mapping technique that can identify structural variants and copy number variations across the entire genome in a single test. The method has been shown to reduce material requirements and improve prognostic stratification for patients with multiple myeloma.
Researchers have received funding to develop a prototype for a new test to monitor people with MGUS, a precursor condition of multiple myeloma. The test aims to detect increases in monoclonal protein and identify patients who need hospital referral for early treatment.
A new study suggests that CT scans could account for 5% of all cancer cases each year, primarily due to radiation exposure. The largest risk is among infants, followed by children and adolescents. To mitigate this risk, reducing the number of scans and doses per scan can help save lives.
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
Researchers found explosive growth rates of cancerous cells years before diagnosis, with variation in growth rates between patients. The study suggests that a single genetic variation drives the disease, making it an outlier compared to other cancers.
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
Researchers at UT Health San Antonio have identified a novel drug target for acute myeloid leukemia, which showed significant delays in disease progression and improved survival rates. The protein paraspeckle component 1 (PSPC1) plays a crucial role in the disease, and targeting it may offer new treatment options for AML patients.
A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.
Researchers at Cornell University discovered that the FGR protein can induce cell differentiation in leukemia cells similar to retinoic acid treatment. The presence of FGR alone was enough to make these cells mature, producing well-known markers of maturation and expressing inhibitor of the cell cycle p27.
Yali Dou, a molecular biologist at Keck School of Medicine of USC, has been elected as an AAAS fellow for her groundbreaking work in understanding leukemia and cancer. Her research on mixed-lineage leukemia proteins has led to the development of potential cancer treatments and a deeper understanding of epigenetics.
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
Researchers developed a microfluidic device to alleviate limitations of conventional blood-filtering machines used in treating hyperleukocytosis in children. The new device separates blood cells by size without platelet loss or adverse effects, enabling safe leukapheresis procedures.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
Researchers found genetic changes in frequent blood donors that enable them to respond well to blood loss, promoting healthy stem cell growth. In contrast, preleukemic mutations associated with blood cancer were not favored by regular donation.
Researchers at Kyushu University have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs. By analyzing cerebrospinal fluid, they identified specific proteins associated with an immune response that can affect the central nervous system after therapy.
The Damon Runyon Cancer Research Foundation has named 13 new Fellows, awarding them $300,000 each to investigate cancer causes and mechanisms. Five recipients of the Dale F. Frey Award for Breakthrough Scientists will also receive an additional $100,000 investment to catapult their research careers.